Manufacture and Clinical Results Using Tumour Infiltrating Lymphocytes for Metastatic Cutaneous, Uveal and Mucosal Melanoma in the UK

摘要

The prognosis for metastatic melanoma remains poor and despite the success of novel antibody-based immunotherapeutics there exists an unmet need for new approaches to treatment. T-cell therapies have shown remarkable efficacy in clinical trials with engineered T-cells heralding a breakthrough which has transposed to the treatment of other cancer indications with TCR and CAR-modified cells. However, natural T-cells isolated from the tumour mass can themselves have substantial anti-cancer properties with numerous reports highlighting the safety and efficacy of melanoma tumour infiltrating lymphocytes (TIL) for the treatment of this disease.